Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review

被引:56
作者
Blinman, Prunella [1 ]
Alam, Mahmood [2 ]
Duric, Vlatka [1 ]
McLachlan, Sue-Anne [3 ,4 ]
Stockler, Martin R. [1 ,5 ]
机构
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW 1450, Australia
[2] Liverpool Canc Therapy Ctr, Liverpool, NSW BC 1871, Australia
[3] St Vincents Hosp, Fitzroy, Vic 3065, Australia
[4] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
[5] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia
基金
英国医学研究理事会;
关键词
Non-small-cell lung cancer; Chemotherapy; Preferences; Decision-making; Patients; Trade-offs; ADJUVANT CHEMOTHERAPY; REFERRAL PATTERNS; ATTITUDES; CISPLATIN; SURVIVAL; JAPAN; CARE;
D O I
10.1016/j.lungcan.2010.05.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Decisions about chemotherapy for NSCLC are complex and involve trade-offs between its benefits, harms and inconveniences. We sought to find, evaluate and summarise studies quantifying the survival benefits that cancer patients judged sufficient to make chemotherapy for NSCLC worthwhile. Methods: A search of MEDLINE identified 5 papers reporting four studies including 270 patients. Two investigators independently extracted and tabulated relevant findings from each study. Results: Most cancer patients were male, aged over 65 years, had primary lung cancer (65%) and had experienced chemotherapy (62%). Preferences were determined for chemotherapy in metastatic NSCLC (3 papers) and in locally advanced NSCLC (2 papers), but no studies determined preferences for adjuvant chemotherapy. Most cancer patients (>50%) judged moderate survival benefits sufficient to make chemotherapy worthwhile, for example, absolute increases of 10% in survival rates or 6 months in life expectancies. Individual patients' preferences varied widely: benefits judged sufficient ranged from very small (e.g. survival rate of 1%) to very large (e.g. survival rate of 50%). Smaller benefits were judged sufficient to make chemotherapy worthwhile for metastatic rather than locally advanced disease, for less toxic rather than more toxic chemotherapy, and in North American rather than Japanese studies. Four baseline characteristics were weakly associated with judging smaller benefits sufficient: younger age, having dependents, tertiary education and worse quality of life. Conclusions: The survival benefits patients judged sufficient to make chemotherapy for NSCLC worthwhile were moderate, widely variable, and difficult to predict. Doctors should encourage patients to express their preferences when facing decisions about chemotherapy for NSCLC. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 35 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]  
*AM COLL SURG, 2009, NAT CANC DAT BENCHM
[3]  
[Anonymous], P AM SOC CLIN ONCOL
[4]   Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life - A randomized controlled trial [J].
Belani, Chandra P. ;
Pereira, Jose R. ;
von Pawel, Joachim ;
Pluzanska, Anna ;
Gorbounova, Vera ;
Kaukel, Eckhard ;
Mattson, Karin V. ;
Ramlau, Rodryg ;
Szczesna, Aleksandra ;
Fidias, Panos ;
Millward, Michael ;
Fossella, Frank .
LUNG CANCER, 2006, 53 (02) :231-239
[5]   Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? [J].
Blinman, Prunella ;
Duric, Vlatka ;
Nowak, Anna K. ;
Beale, Philip ;
Clarke, Stephen ;
Briscoe, Karen ;
Boyce, Adam ;
Goldstein, David ;
Hudson, Malcolm ;
Stockler, Martin .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) :1800-1807
[6]   Trading treatment toxicity for survival in locally advanced non-small cell lung cancer [J].
Brundage, MD ;
Davidson, JR ;
Mackillop, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :330-340
[7]   Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer [J].
Brundage, MD ;
Feldman-Stewart, D ;
Cosby, R ;
Gregg, R ;
Dixon, P ;
Youssef, Y ;
Davies, D ;
Mackillop, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1326-1335
[8]   Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support [J].
Brundage, MD ;
Feldman-Stewart, D ;
Cosby, R ;
Gregg, R ;
Dixon, P ;
Youssef, Y ;
Mackillop, WJ .
PATIENT EDUCATION AND COUNSELING, 2001, 45 (02) :149-157
[9]   Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer [J].
Brundage, MD ;
Davidson, JR ;
Mackillop, WJ ;
Feldman-Stewart, D ;
Groome, P .
MEDICAL DECISION MAKING, 1998, 18 (03) :256-267
[10]   Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group [J].
Burdett, S. ;
Stephens, R. ;
Stewart, L. ;
Tierney, J. ;
Auperin, A. ;
Le Chevalier, T. ;
Le Pechoux, C. ;
Pignon, J. P. ;
Arriagada, R. ;
Higgins, J. ;
Johnson, D. ;
van Meerbeeck, J. ;
Parmar, M. ;
Souhami, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4617-4625